Financial Toxicity in Oncology, More Unanswered Questions – PubMed
Financial Toxicity in Oncology, More Unanswered Questions
Related Articles
Closed Borders of our Empathy — Critical Forced Displacement
Dr. Alina Sadaf, MD recounts her experiences as a pediatric oncologist working with Afghan refugees in Lahore, Pakistan.
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant – Full Text View – ClinicalTrials.gov
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant – Full Text View.
Dietary interventions in cancer: a systematic review of all randomized controlled trials
AbstractBackground. Prior systematic reviews addressing the impact of diet on cancer outcomes have focused on specific dietary interventions. In this systematic
Dietary interventions in cancer: a systematic review of all randomized controlled trials
AbstractBackground. Prior systematic reviews addressing the impact of diet on cancer outcomes have focused on specific dietary interventions. In this systematic
Episode 24: Myeloma Madness with the Myeloma Man by WolverHeme Happy Hour
In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in…
Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation
In March 1998, Common Toxicity Criteria (CTC) version 2.0 introduced the collection of attribution of adverse events (AEs) to study drug. We investigate whether attribution…
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial
Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid…
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Blood Cancer Journal – In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation
In March 1998, Common Toxicity Criteria (CTC) version 2.0 introduced the collection of attribution of adverse events (AEs) to study drug. We investigate whether attribution…
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis – PubMed
Use of surrogate end-points such as progression-free survival (PFS) and other time-to-event (TTE) end-points is common in multiple myeloma (MM) clinical trials. This systematic review…